Influenza (the flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and at times can lead to death. The best way to prevent the flu is by getting a flu vaccination each year. Every year in the United States, on average 5% to 20% of the population gets the flu; more than 200,000 people are hospitalized from flu complications, and; about 36,000 people die from flu-related causes. Some people, such as older people, young children, and people with certain health conditions, are at high risk for serious flu complications.
As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin-Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.
Using innovative computer-based approaches, researchers have developed protein inhibitors that block the interaction between the SARS-CoV-2 virus and human cell receptor ACE2.
A major percentage of COVID-19 cases have become so severe that hospital admissions have become mandatory for both monitoring and treatment.
Zika virus infection during pregnancy can cause severe abnormalities in the fetus, including malformations such as microcephaly. In a small proportion of cases, the disease may lead to miscarriage and perinatal death.
For a long time, influenza scientists have largely focused their studies on the epithelial cells that line the lungs.
Small-scale poultry farmers in Vietnam tend to respond to viral outbreaks of highly pathogenic avian influenza (HPAI) by rapidly selling their birds as a way to avoid financial loss, according to a new study by an international team of researchers.
A research group composed of Professor Takayuki Shibata and his colleagues at the Department of Mechanical Engineering, Toyohashi University of Technology has applied a microfluidic chip technology to develop a multiplex genetic diagnostic device for the early detection and prevention of crop diseases.
Influenza viruses can spread through the air on dust, fibers and other microscopic particles, according to new research from the University of California, Davis and the Icahn School of Medicine at Mt. Sinai.
Unlike living organisms, to avoid extinction, viruses need to hijack living host machineries to generate new viruses.
A study from Emory Vaccine Center provides insights into why the boost in immunity from seasonal flu vaccination lasts for months but not years, unlike some childhood vaccinations.
The immune system secretes an endogenous protein that can strongly suppress coronaviruses, the pathogen that is responsible for causing the current pandemic.
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease.
Human-resident microbes can influence both health and disease. Investigating the microbiome using next-generation sequencing technology has revealed examples of mutualism and conflict between microbes and humans.
A rapid laboratory test, the eosinophil count, readily obtained from a routine complete blood cell count (CBC) can aid in the early recognition of COVID-19 in patients, as well as provide prognostic information, according to new research in The Journal of the American Osteopathic Association.
Approximately 5% of people with Covid-19 progress to a severe or critical form, including the development of severe pneumonia that progresses to acute respiratory distress syndrome.
A single dose of the flu drug baloxavir marboxil can reduce the spread of the illness within households, new research concludes.
Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
Scientists have created a human cell “membrane on a chip” that enables tracking of the interaction of drugs and infectious agents with the human cells.
Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly's next-generation anti-SARS-CoV-2 antibodies.
An international team of researchers has analyzed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells.